 Naltrexone
"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 2 | 3 | | 1994 | 1 | 3 | 4 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 1 | 3 | | 2000 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2007 | 3 | 0 | 3 | | 2008 | 3 | 0 | 3 | | 2010 | 2 | 0 | 2 | | 2012 | 1 | 0 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 0 | 2 | 2 | | 2015 | 3 | 1 | 4 | | 2016 | 0 | 2 | 2 | | 2017 | 1 | 0 | 1 | | 2018 | 5 | 1 | 6 | | 2019 | 2 | 1 | 3 | | 2020 | 4 | 0 | 4 | | 2021 | 1 | 1 | 2 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Terasaki D, Loh R, Cornell A, Taub J, Thurstone C. Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates. Addict Sci Clin Pract. 2022 Nov 22; 17(1):64.
-
Chockalingam L, Burnham EL, Jolley SE. Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system. Alcohol Clin Exp Res. 2022 06; 46(6):1094-1102.
-
Schacht JP, Hoffman M, Chen BH, Anton RF. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
-
Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021 08 01; 225:108764.
-
Szczesniak LM, Calleo VJ, Sullivan RW. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report. Harm Reduct J. 2020 10 07; 17(1):71.
-
Anton RF, Voronin KE, Book SW, Latham PK, Randall PK, Glen WB, Hoffman M, Schacht JP. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
-
Kwilasz AJ, Todd LS, Duran-Malle JC, Schrama AEW, Mitten EH, Larson TA, Clements MA, Harris KM, Litwiler ST, Wang X, Van Dam AM, Maier SF, Rice KC, Watkins LR, Barrientos RM. Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone. Behav Brain Res. 2021 01 01; 396:112896.
-
Boudreau DM, Lapham G, Johnson EA, Bobb JF, Matthews AG, McCormack J, Liu D, Campbell CI, Rossom RC, Binswanger IA, Yarborough BJ, Arnsten JH, Cunningham CO, Glass JE, Murphy MT, Zare M, Hechter RC, Ahmedani B, Braciszewski JM, Horigian VE, Szapocznik J, Samet JH, Saxon AJ, Schwartz RP, Bradley KA. Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. J Subst Abuse Treat. 2020 03; 112S:41-48.
-
Hartwell EE, Feinn R, Morris PE, Gelernter J, Krystal J, Arias AJ, Hoffman M, Petrakis I, Gueorguieva R, Schacht JP, Oslin D, Anton RF, Kranzler HR. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
-
Jewett DC, Klockars A, Smith TR, Brunton C, Head MA, Tham RL, Kwilasz AJ, Hahn TW, Wiebelhaus JM, Ewan EE, Carroll RM, Grace MK, Levine AS, Olszewski PK. Effects of opioid receptor ligands in rats trained to discriminate 22 from 2 hours of food deprivation suggest a lack of opioid involvement in eating for hunger. Behav Brain Res. 2020 02 17; 380:112369.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|